(A), IB analysis for expression of GFP, CANX and exosomal marker CD9
in parental PC3, EGFP-PC3 (Mock) and β6-EGFP-PC3 derived
exosome lysate (Exo) and total cell lysate (TCL). (B), Left,
Iodixanol gradient analysis of β6-EGFP-PC3 derived Exo was
performed as described in the Experimental Procedures. Expression of
β6, CD63, and CD81 analyzed by IB is shown. The expected
density range for Exo is 1.11–1.14 g/mL. Right, NTA for the fifth
fraction (density 1.14 g/mL) from the iodixanol gradient of
β6-EGFP-PC3 derived Exo is shown. (C), Left,
human normal PBMC (2.0×105 cells) incubated with 8
μg/mL of β6-EGFP-PC3 Exo for 36 hours, were
immuno-stained for CD14. Flow cytometric contour plots of cells gated as
CD14+ monocytes are shown. Middle, flow cytometric
analysis of comparative expression of GFP measured as mean fluorescence
intensity (MFI) in PBMC incubated with parental PC3 or
β6-EGFP-PC3 Exo (8 μg/mL for 36 hours). Right, flow
cytometric analysis of comparative expression of CD163 (M2 macrophage marker)
measured as MFI in PBMC incubated with or without parental PC3 (8 μg/mL
for 36 hours). Two graphs showing GFP and CD163 MFI include data from 4
biological replicates tested in 2 different experiments. **:
P >0.01, student’s T test.